Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
2022-06-30
عنوان الدراسة
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
داعم الدراسة
Hikma
دواء الدراسة
Dasatinib
رقم بروتوكول الدراسة
LPI-JOR-LEB-KSA-TUN-
حالة الدراسة
Rejected
موقع الدراسة
KFSH & RC - R
مرحلة الدراسة
2
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.